Lyell Immunopharma, Inc. LYEL
10.77 USD -0.11 (-1.01%)
At closeNov 3, 2026, 4:00 PM EST
10.77 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
10.58 Day range 11.59
7.20 52-week range 45.00
- YTD
- -65.01%
- 1 year
- -34.92%
Financial health
Altman Z-Score
-7.51 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
1 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C+2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 4
Valuation
P/E -1.9×
FY 2019 5y median -41.5× FY 2025
P/S 14615×
FY 2019 5y median 2743× FY 2025
P/B 2.1×
FY 2019 5y median 1.0× FY 2025
P/FCF -3.5×
FY 2019 5y median -3.5× FY 2025
EV/EBITDA -2.0×
FY 2019 5y median -2.0× FY 2025
EV/Sales 14359×
FY 2019 5y median 1979× FY 2025
FCF Yield -28.7%
FY 2019 5y median -28.7% FY 2025
Profitability
Gross Margin -31952.8%
FY 2019 5y median 100.0% FY 2025
Operating Margin -566038.9%
FY 2019 5y median -190006.2% FY 2025
Net Margin -762355.6%
FY 2019 5y median -180486.2% FY 2025
ROE -110.6%
FY 2019 5y median -35.8% FY 2025
ROIC -68.0%
FY 2019 5y median -34.2% FY 2025
ROA -80.7%
FY 2019 5y median -31.3% FY 2025
Growth (YoY)
Revenue -41.0%
FY 2019 FY 2025
Operating Income 43.2%
FY 2019 FY 2025
EPS (diluted) -1126.0%
FY 2019 FY 2025
Free Cash Flow 7.4%
FY 2019 FY 2025
Financial Health
Current Ratio 5.3×
FY 2019 5y median 13.4× FY 2025
Quick Ratio 5.3×
FY 2019 5y median 13.4× FY 2025
Debt / Equity 0.2×
FY 2019 5y median 0.1× FY 2025
Net Debt / EBITDA 0.0×
FY 2019 5y median 0.3× FY 2025
Interest Coverage 0.0×
FY 2019 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31